Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

Lawry Han

Status: Completed

Conditions: Blood Sugar; High; Overweight and Obesity; Glucagon; GLP-1; Fat Loss

Treatments: Dietary Supplement: GB; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07141472

AB20241210H

Details and patient eligibility

About

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.

PURPOSE In prior study, GB was clinically shown to reduce blood sugar level, increase GLP-1 production, and help body fat loss. The purpose of this RCT study is to further assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula vs placebo, in the hope of confirming the efficacy and safety of GB.

SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, this study is a randomized controlled clinical trial for a total of 26 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints (week 0, 13 and 26).

Enrollment: 69 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Volunteers must be over the age of 18.
• Volunteers cannot be smokers.
• Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
• Exercising volunteers must maintain their regimen consistently throughout the course of the 26-week study.
• Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 26-week study.
• Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

69 participants in 2 patient groups, including a placebo group

Active Group who take GB

Experimental group

Description:

GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.

Treatment:

Dietary Supplement: GB

Placebo Group

Placebo Comparator group

Description:

Placebo is a product that resemble Active product but does not contain any of the active ingredients.

Treatment:

Dietary Supplement: Placebo